Brief: Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises

Beam Therapeutics

13/01/2025 13:37

Jan 13 (Reuters) - Beam Therapeutics Inc  BEAM.O :
    * BEAM THERAPEUTICS ANNOUNCES PROGRESS IN HEMATOLOGY AND
GENETIC
DISEASE FRANCHISES AND OUTLINES KEY 2025 ANTICIPATED CATALYSTS
    * EXPECTS TO DOSE 30 PATIENTS AND PRESENT DATA BY MID-2025
    * INITIAL DATA FROM BEAM-302 TRIAL EXPECTED IN FIRST HALF
2025
    * DOSING TO COMMENCE IN BEAM-301 TRIAL IN EARLY 2025
    * CASH RUNWAY EXPECTED TO SUPPORT OPERATIONS INTO 2027
    * OVER 40 ADULT SICKLE CELL PATIENTS ENROLLED IN BEACON
TRIAL

Source text:  ID:nGNX10kVtv 
Further company coverage:  BEAM.O 

 ((Reuters.Briefs@thomsonreuters.com;))